Bolder BioTechnology receives United States patent for modified human growth hormone.Bolder BioTechnology, Inc. (Wheat Ridge, CO) has been granted United States Patent 6,608,183 by the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property . Joe Cox, company President, said, "The patent's claims cover cysteine cysteine (sĭs`tēn), organic compound, one of the 20 amino acids commonly found in animal proteins. Only the l-stereoisomer participates in the biosynthesis of mammalian protein. analogs and modified cysteine analogs of human growth hormone human growth hormone (HGH): see growth hormone. and growth hormone growth hormone or somatotropin (sōmăt'ətrō`pən), glycoprotein hormone released by the anterior pituitary gland that is necessary for normal skeletal growth in humans (see protein). antagonists. The cysteine analogs permit targeted modification of growth hormone and growth hormone antagonists with large polymers such as polyethylene glycol (PEG), which are useful for creating long-acting protein therapeutics. Targeted attachment of PEG to growth hormone results in a homogeneously modified protein with high biological activity and overcomes the problems of product heterogeneity and loss of activity that occurs when growth hormone is modified using non-targeted PEGylation technologies. Our long-acting growth hormone product was created using this targeted PEGylation technology and is being developed as a potential treatment for growth hormone deficiency growth hormone deficiency Hypopituitarism Endocrinology A condition which affects 1:4000 children; ♂:♀, 3-4:1 Etiology 70% of GHD is idiopathic and attributed to a prenatal insult, possibly due to hypothalamic dysfunction, given that GHD children in children and adults. Currently marketed growth hormone products must be administered by daily injection, which represents a significant burden for patients, particularly children, who must take the drug for years. Our long-acting growth hormone product is expected to be more patient-friendly, with an anticipated dosing frequency of only once every one to two weeks." Bolder BioTechnology uses protein engineering technologies to create long-acting human protein pharmaceuticals for the treatment of hematopoietic hematopoietic /he·ma·to·poi·et·ic/ (-poi-et´ik) 1. pertaining to hematopoiesis. 2. an agent that promotes hematopoiesis. hematopoietic 1. pertaining to or affecting the formation of blood cells. and endocrine disorders, cancer and infectious diseases. Research leading to the development of the company's long acting growth hormone analogs has been supported by two Small Business Innovation Research grants awarded to Bolder BioTechnology by the National Institute of Diabetes and Digestive and Kidney Diseases About NIDDK The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), of the U.S. National Institutes of Health, conducts and supports research on many of the most serious diseases affecting public health. of the National Institutes of Health. Bolder BioTechnology, Inc. +1-303-420-4420 www.bolderbio.com |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion